IU researchers uncover mysteries behind immune response to hemophilia A treatment
Indiana UniversityPatients with the genetic disorder hemophilia A receive factor VIII protein replacement treatments to replenish this clotting protein in their blood, thus preventing dangerous bleeding. Unfortunately, about 30 percent of these patients develop antibodies against the treatment and until now, despite more than 80 years of clinical experience with this complication, little has been known about its mechanism.